Abstract Introduction Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) is the first direct-
acting antiviral (DAA) therapy approved for patients who have previously failed a DAA …

The approval of combination therapies with direct-acting antiviral (DAA) regimens has led to
significant progress in the field of hepatitis C virus (HCV) treatment. Although most patients …

Background & Aims Voxilaprevir/velpatasvir/sofosbuvir (VOX/VEL/SOF) is highly effective for
re-treatment of direct-acting antiviral (DAA)-experienced patients with chronic HCV infection …

Virological failure occurs in a small proportion of people treated for hepatitis C virus (HCV)
with direct‐acting antiviral (DAA) therapies. This study assessed retreatment for virological …

Conclusions: Patients infected with “unusual” HCV genotype 1 subtypes are over-
represented among direct-acting antiviral treatment failures. Most of them were born and …

Hepatitis C virus (HCV) remains a major global health concern. Directly acting antiviral
(DAA) drugs have transformed the treatment of HCV. However, it has become clear that …

Background: World Health Organization has called for research into predictive factors for
selecting persons who could be successfully treated with shorter durations of direct-acting …

Abstract Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for
HCV patients with prior failure to DAA therapy. Additionally, all patients either maintained or …

Background Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended
rescue therapy for patients with chronic hepatitis C infection who fail direct‐acting antivirals …

Introduction: Despite the overall excellent efficacy of pangenotypic direct-acting antiviral
(DAA) options, there is still a small percentage of patients with hepatitis C virus (HCV) …